Black Diamond Therapeutics, Inc.
US ˙ NasdaqGS ˙ US09203E1055

SecurityBDTX / Black Diamond Therapeutics, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership17,150 shares
Latest Disclosed Value $ 36,530
Prudential Financial Inc reports 33.46% increase in ownership of BDTX / Black Diamond Therapeutics, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 17,150 shares of Black Diamond Therapeutics, Inc. (US:BDTX) valued at $36,530 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 12,850 shares of Black Diamond Therapeutics, Inc.. This represents a change in shares of 33.46% during the quarter. The current value of the position is $35,844 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F LACK DIAMOND THERAPEUTICS I COM 09203E105 17,150 4,300 33.46 37 16.13 0.0000
2026-02-13 2025-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 12,850 -250 -1.91 31 -36.73 0.0000
2025-11-13 2025-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 13,100 0 0.00 50 53.13 0.0001
2025-08-12 2025-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 13,100 13,100 32 0.0000
2021-05-12 2021-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 0 -37,490 -100.00 0 -100.00
2021-08-16 2020-12-31 13F/A-1 BLACK DIAMOND THERAPEUTICS I COM 0032 09203E105 37,490 16,350 77.34 1,202 88.11 0.0020
2021-02-16 2020-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 37,490 16,350 1,202 0.0020
2020-11-16 2020-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 21,140 180 0.86 639 -27.63 0.0012
2020-08-12 2020-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 20,960 50 0.24 883 69.16 0.0017
2020-05-12 2020-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 20,910 20,910 522 0.0012
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.